Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 601–700 of 1,004
Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression
Tzamali, E., Sakkalis, V., Tzedakis, G., Spanakis, E. G., & Tzanakis, N. (2023) · Vaccines · doi:10.3390/vaccines11040722 · Cited by 13
Li, Y., Gong, Y., & Xu, G. (2023) · QJM · doi:10.1093/qjmed/hcad159 · Cited by 15
Mathematical modeling for Delta and Omicron variant of SARS-CoV-2 transmission dynamics in Greece
Liossi, S., Tsiambas, E., Maipas, S., Papageorgiou, E., Lazaris, A. C., & Kavantzas, N. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.07.002 · Cited by 14
“…the gradual weakening of immunity of vaccinated and recovered individuals, but assumes that recovered individuals have natural immunity for 6months, and after this period they are considered to be susceptible to get infected again (Goldberg et al., 2022; Levin et al., 2021; Thomas et al., 2021).”
Søndergaard, M. H., Thavarajah, J. J., Henson, H. C., & Wejse, C. M. (2023) · HIV Medicine · doi:10.1111/hiv.13537 · Cited by 13
Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics
Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34577 · Cited by 14
“Moreover, such vaccines are capable of inducing S antigen-specific IgA and IgG antibodies that sustain high titers six months following the second vaccination dose [101,102].”
BackgroundVaccines for Respiratory Viruses—COVID and Beyond
Rajanala, K., & Upadhyay, A. (2024) · Vaccines · doi:10.3390/vaccines12080936 · Cited by 13
“The Pfizer-BioNTech’s (BNT162b2) [23,24] and Moderna’s (mRNA-1273) [25,26] vaccines, which utilized mRNA technology, were among the first to receive Emergency Use Authorization (EUA) from the U.S. FDA in December 2020.”
BackgroundShim, C. Y., Chan, S. Y., Wei, Y., Ghani, H., Ahmad, L., Sharif, H., Alikhan, M. F., Bagol, S. H., Taib, S., Tan, C. W., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.983571 · Cited by 14
Schwab, C., Merle, U., Schirmacher, P., & Longerich, T. (2023) · Histopathology · doi:10.1111/his.14931 · Cited by 13
“The continuous evolution of the SARSCoV-2 genome resulted in the development of immune-evasive mutations in the spike protein.(9,10) Due to these mutations, the neutralising efficacy of the first-generation SARS-CoV-2 vaccines was mitigated, leading to restricted protection against infections in the setting of steadil…”
BackgroundClifford, S., Waight, P., Hackman, J., Hué, S., Gower, C., Kirsebom, F. C. M., Skarnes, C., Letley, L. H., Bernal, J. L., Andrews, N. J., et al. (2021) · medRxiv · doi:10.1101/2021.11.24.21266401 · Cited by 15
Brownstein, J. S., Cantor, J., Rader, B. M., Simon, K. I., & Whaley, C. (2022) · National Bureau of Economic Research · doi:10.3386/w30429 · Cited by 14
Covid-19 Rates by Time since Vaccination during Delta Variant Predominance
Paz‐Bailey, G., Sternberg, M., Kugeler, K. J., Hoots, B., Amin, A. B., Johnson, A. G., Barbeau, B., Bayoumi, N. S., Bertolino, D., Boulton, R., et al. (2021) · NEJM Evidence · doi:10.1056/evidoa200057 · Cited by 12
Jonny, J., Putranto, T. A., Yana, M. L., Sitepu, E. C., Irfon, R., Ramadhani, B. P., Sofro, M. A. U., Nency, Y. M., Lestari, E. S., Triwardhani, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122389 · Cited by 12
Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies
Barosa, M., Ioannidis, J. P. A., & Prasad, V. K. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14286 · Cited by 12
“From 2021 onwards, the rise of immune evasive variants and waning vaccine-induced immunity 24 led to plummet-ing vaccine effectiveness against symptomatic disease (not necessarily severe disease), and booster doses were widely recommended.”
Soldatov, A. A., Kryuchkov, N. A., Витальевич, Г. Д., Авдеева, Ж. И., Свитич, О. А., & Soshnikov, S. S. (2025) · Vaccines · doi:10.3390/vaccines13080789 · Cited by 13
“For instance, the disease (of any severity) prevention efficacy of the Comirnaty vaccine (BNT162b2) decreased from 90% to 60% six months after vaccination [5].”
Szebeni, J., & Koller, Á. (2025) · Vaccines · doi:10.3390/vaccines13080855 · Cited by 13
Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers
Heyming, T. W., Nugent, D. J., Tongol, A., Knudsen-Robbins, C., Hoang, J., Schomberg, J., Bacon, K., Lara, B., & Sanger, T. D. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.065 · Cited by 12
Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
Yadav, P. D., & Kumar, S. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00687-3 · Cited by 12
Breakthrough infections with the SARS-CoV-2 Delta variant: vaccinations halved transmission risk
Hsu, L. Y., Hurraß, J., Kossow, A., Klobucnik, J., Nießen, J., Wiesmüller, G. A., Grüne, B., & Joisten, C. (2022) · Public Health · doi:10.1016/j.puhe.2022.01.005 · Cited by 12
Peter, J. K., Wegner, F., Gsponer, S., Helfenstein, F., Roloff, T. C., Tarnutzer, R., Grosheintz, K., Back, M., Schaubhut, C., Wagner, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050857 · Cited by 13
COVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study
Valladares-Garrido, M. J., Zeña-Ñañez, S., Peralta, C. I., Puicón-Suárez, J. B., Díaz-Vélez, C., & Failoc‐Rojas, V. E. (2022) · Vaccines · doi:10.3390/vaccines10050812 · Cited by 14
“Studies have demonstrated that vaccinated people present immunity up to 6 months after a second dose, in comparison with unvaccinated people [13].”
BackgroundTsundue, T., Namdon, T., Tsewang, T., Topgyal, S., Dolma, T., Lhadon, D., Choetso, T., Woesal, T., Yangkyi, T., Gupta, A., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2021-008271 · Cited by 10
Kanai, D., Wakui, H., Haze, T., Azushima, K., Kinguchi, S., Tsukamoto, S., Kanaoka, T., Urate, S., Toya, Y., Hirawa, N., et al. (2022) · Clinical and Experimental Nephrology · doi:10.1007/s10157-022-02243-8 · Cited by 12
“Several types of vaccine against SARS-CoV-2 have been developed, of which mRNA vaccines are the most widely used because they can efficiently prevent severe illness, hospitalization, and death [1, 2].”
BackgroundPark, H.-S., Matsuoka, Y., Luongo, C., Yang, L., Santos, C. P., Liu, X., Ahlers, L. R. H., Moore, I. N., Afroz, S., Johnson, R. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00493-x · Cited by 14
The design and analysis of vaccine trials for COVID ‐19 for the purpose of estimating efficacy
Senn, S. J. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2226 · Cited by 12
Mazagatos, C., Delgado‐Sanz, C., Monge, S., Pozo, F., Oliva, J. A., Sandonis, V., Gandarillas, A., Rubio, C. Q., Ruiz‐Sopeña, C., García, V. G., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13026 · Cited by 13
Clinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 14
Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany
Walach, H., Ofner, M., Ruof, V., Herbig, M., & Klement, R. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060555 · Cited by 14
Applications and challenges of biomaterial mediated mRNA delivery
Fang, H., & Chen, Q. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00093 · Cited by 13
Hooper, A. T., Somersan-Karakaya, S., McCarthy, S., Mylonakis, E. E., Ali, S., Mei, J., Bhore, R., Mahmood, A., Geba, G. P., Dakin, P., et al. (2022) · mBio · doi:10.1128/mbio.01699-22 · Cited by 12
Wichaidit, M., Nopsopon, T., Sunan, K., Phutrakool, P., Ruchikachorn, P., Wanvarie, D., Pratanwanich, P. N., Cheewaruangroj, N., Punyabukkana, P., & Pongpirul, K. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100106 · Cited by 14
A comprehensive review on various aspects of SARS-CoV-2 (COVID-19) vaccines
Mazaheri, E., Pordanjani, A. R., Pordanjani, A., Askarpour, H., Arjmand, M., Babakhanian, M., & Amiri, M. (2022) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_513_21 · Cited by 12
“To store for more than 10 days, a much lower temperature is required.[22] This vaccine as a series of two doses of 0.”
BackgroundKapten, K., Orczyk, K., & Smolewska, E. B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00673-0 · Cited by 14
“However, the decline of vaccine efficacy in preventing viral transmission over time, is one of the leading concerns regarding vaccine protection in the long term (Daković et al. 2022; Thomas et al. 2021).”
BackgroundSager, J. E., El‐Zailik, A., Passarell, J. A., Roepcke, S., Li, X., Aldinger, M., Nader, A., Skingsley, A., Alexander, E. L., Yeh, W. W., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12958 · Cited by 12
“(1) characterize the PopPK of sotrovimab following i.”
BackgroundMatson, R., Niesen, M. J. M., Levy, E. R., Opp, D. N., Lenehan, P. J., Donadio, G., O’Horo, J. C., Venkatakrishnan, A., Badley, A. D., & Soundararajan, V. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00253-9 · Cited by 13
Langlete, P., Tesli, M., Veneti, L., Starrfelt, J., Elstrøm, P., & Meijerink, H. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.022 · Cited by 12
Elamin, M. Y., Maslamani, Y. A., Muaddi, M. A., Alameer, A. A., Alqassim, A. Y., Doweri, A. A., Zaylaee, M. M., Rayani, H. Y., Darraj, A., Hejri, Y. M., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.06.014 · Cited by 12
“One of the earliest ones underscored the effectiveness of two Pfizer vaccine doses based on the findings of a clinical trial that recruited 43,548 people aged 16 years and older between July and November 2020 from 152 sites in the United States, Argentina, Brazil, South Africa, Germany, and Turkey.”
InfluentialTavazzi, E., Pichiecchio, A., Colombo, E., Rigoni, E., Asteggiano, C., Vegezzi, E., Masi, F., Greco, G., Bastianello, S., & Bergamaschi, R. (2023) · Viruses · doi:10.3390/v15071569 · Cited by 13
Bone marrow alterations in COVID-19 infection: The root of hematological problems
Zeylabi, F., Fard, N. N. G., Parsi, A., & Pezeshki, S. M. S. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103407 · Cited by 13
Hejazi, N. S., Shen, X., Carpp, L. N., Benkeser, D. C., Follmann, D. A., Janes, H., Baden, L. R., Sahly, H. M. E., Deng, W., Zhou, H., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.012 · Cited by 15
Michels, C. A., Perrier, D., Kunadhasan, J., Clark, E., Gehrett, J., Gehrett, B., Kwiatek, K., Adams, S., Chandler, R. W., Stagno, L., et al. (2023) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v3i1.85 · Cited by 12
Li, X., Peng, P., Deng, H., Yang, Q., Chen, S., Li, B., He, M., Jin, A., Yang, Z., Tang, N., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01656-5 · Cited by 12
“Although vaccination has played important roles in preventing and controlling COVID-19 1,2 , the neutralizing antibodies (NAbs) elicited by vaccines were heterogeneous among different individuals and were waning within several months 3 – 5 .”
BackgroundSelf-citationO’Neill, A., Mantri, C. K., Tan, C. W., Saron, W. A. A., Nagaraj, S. K., Kala, M. P., Joy, C. M., Rathore, A. P. S., Tripathi, S., Wang, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104924 · Cited by 12
Matei, D. V., Trăistaru, R., Amzolini, A. M., Ianoși, S. L., Neagoe, C. D., Mitrea, A., Clenciu, D., & Avramescu, T. E. (2024) · Life · doi:10.3390/life14080942 · Cited by 12
“This type of vaccine has been associated with an increased incidence of new cases of myocarditis [45], multiple sclerosis [46], systemic lupus erythematosus [47], connective tissue diseases, and inflammatory arthritis [48].”
BackgroundTourki, B., Jia, M., Karampitsakos, Τ., Vera, I., Arsenault, A., Fatima, Z., Perrot, C. Y., Allen, D., Farsaei, F., Rutenberg, D., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00528.2024 · Cited by 13
Plumb, I. D., Fette, L. M., Tjaden, A. H., Feldstein, L. R., Saydah, S., Ahmed, A., Link‐Gelles, R., Wierzba, T. F., Berry, A. A., Friedman-Klabanoff, D. J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.006 · Cited by 12
“…after Pfizer BioNTech vaccine and 92% after Moderna vaccine were similar to estimates against symptomatic infection reported in respective clinical trials [14,15], and to estimates against any infection or asymptomatic infection from several observational studies during the same period [1,16,17].”
Huiberts, A. J., Hoeve, C. E., Kooijman, M. N., de Melker, H. E., Hahné, S. J. M., Grobbee, D. E., van Binnendijk, R. S., den Hartog, G., van de Wijgert, J. H. H. M., van den Hof, S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085388 · Cited by 12
Baum, U., Poukka, E., Leino, T. M., Kilpi, T. M., Nohynek, H., & PALMU, A. A. I. (2022) · medRxiv · doi:10.1101/2022.03.11.22272140 · Cited by 14
Arashiro, T., Miwa, M., Nakagawa, H., Takamatsu, J., Oba, K., Fujimi, S., Kikuchi, H., Iwasawa, T., Kanbe, F., Oyama, K., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.12.033 · Cited by 11
Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization
Ragone, C., Mauriello, A., Cavalluzzo, B., Cavalcanti, E., Russo, L., Manolio, C., Mangano, S., Cembrola, B., Tagliamonte, M., & Buonaguro, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1398002 · Cited by 11
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV
Wang, G., Verma, A. K., Shi, J., Guan, X., Meyerholz, D. K., Bu, F., Wen, W., Liu, B., Li, F., Perlman, S. M., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00922-z · Cited by 13
A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus
Zhang, J., Zhang, J., Wang, Y., Sun, Y., Wang, Y., Wang, Y., Yang, D., Qiao, X., Liu, X., Ding, J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00991-0 · Cited by 11
“The clinical application of both DNA and mRNA vaccines demonstrates their acceptable tolerability 61 – 67 .”
Pan, Y., Han, Y., Zhou, C., Zhao, L., Zheng, J., Ye, X., He, Y. O., & Chute, C. G. (2025) · Nature Communications · doi:10.1038/s41467-025-61613-4 · Cited by 14
“ThedatasetincludesEHRinformationfromover22millionindividuals, encompassing clinical diagnoses, laboratory test results, medication histories, demographics,physiciannotes, and more 19 .”
Roier, S., Adamo, R., Rosini, R., Pezzicoli, A., Scarselli, M., Petsch, B., Jasny, E., & Rauch, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1668937 · Cited by 11
Wu, N. R., Beutler, N., Hu, X., Skog, P. D., Liguori, A., Flores-García, Y., Maiorino, L., Terada, S., Lu, D., Lai, Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01296-6 · Cited by 11
Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
Flisiak, R., Pawłowska, M., Rogalska, M., Bociąga‐Jasik, M., Kłos, K., Piekarska, A., & Zarębska‐Michaluk, D. (2021) · Vaccines · doi:10.3390/vaccines9111325 · Cited by 11
“Discussion In a placebo-controlled study evaluating the long-term efficacy of the BNT162b2 vaccine, carried out after the publication of the registration study results, the effectiveness of the vaccine against COVID-19 at six months of follow-up was 91%, while that against severe disease was 97% [2,3].”
BackgroundVaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population
Weinberger, B. (2021) · Vaccines · doi:10.3390/vaccines9121435 · Cited by 11
“Efficacy and effectiveness against the “early” variants Alpha, Beta, and Gamma have been investigated in numerous studies [61,70,71], but a comprehensive summary of all”
BackgroundImmunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 12
Mochizuki, T., Hori, T., Yano, K., Ikari, K., & Okazaki, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8902-21 · Cited by 11
“The BNT162b2 vaccine had high effectiveness against COVID-19 infection and led to fewer hospital admissions for up to six months (5, 6).”
BackgroundReal-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
Hara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., SAKAMOTO, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050779 · Cited by 11
Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
Luo, C., Du, J., Cuker, A. C., Lautenbach, E., Asch, D. A., Poland, G. A., Tao, C., & Chen, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-13809-7 · Cited by 11
mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks and Coverage.
Nashwan, A. J., Yassin, M. A., Soliman, A. T., Sanctis, V. D., & Ibrahim, M. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i3.13103 · Cited by 14
“1% - 95%) in protecting individuals from COVID-19 and are widely used globally (5-7).”
BackgroundToussia‐Cohen, S., Yinon, Y., Peretz-Machluf, R., Segal, O., Regev, N., Asraf, K., Doolman, R., Kubani, Y., Gonen, T., Regev‐Yochay, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164720 · Cited by 11
“Among the group of pregnant women who received the third vaccine, we demonstrated low levels of serum SARS-CoV-2 IgG antibodies before vaccination, implicating the reduced efficacy of BNT162b2 over time as shown in several recent studies [18,19].”
ResultWang, F., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967051 · Cited by 11
Fedele, G., Palmieri, A., Damiano, C., Lonardo, A. D., Leone, P., Schiavoni, I., Trevisan, C., Abbatecola, A. M., Cafariello, C., Malara, A., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02239-0 · Cited by 14
“Despite the reduction of antibody titers between T1 and T2, most residents were still seropositive, in line with observations showing that vaccine-induced antibodies may last for several months after vaccination [9, 27].”
BackgroundLiposome Nanocarriers for Peptide Drug Delivery
Sonju, J. J., Dahal, A., & Jois, S. D. S. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-04544-8_6 · Cited by 12
Covid-19 third vaccination during pregnancy: maternal and neonatal outcomes—a retrospective study
Rottenstreich, M., Rotem, R., Weil‐Weiner, Y., Grisaru‐Granovsky, S., & Sela, H. Y. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06786-9 · Cited by 11
“Current data demonstrate the efficacy of the two doses—mRNA vaccination for up to 5–6 months, as supported by immunogenicity studies [12, 13].”
BackgroundUptake of COVID-19 booster shot among healthcare workers: A mediation analysis approach
Rehman, S., Rehman, E., & Jianglin, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1033473 · Cited by 11
“Appropriate and reliable preventative vaccinations were thereby a potentially helpful weapon that potentially is adopted to minimize transmission rates and consequent illnesses in response to the outbreak (25, 26).”
BackgroundA systematic review of current status and challenges of vaccinating children against SARS-CoV-2
Zhang, M., Zhang, P., Liang, Y., Du, B., Li, L., Yu, Z., Wang, H., Wang, Q., Zhang, X., & Zhang, W. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.006 · Cited by 11
Chua, T. H., & Takano, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216290 · Cited by 8
“3% after 6 months of follow-up has been reported [5].”
BackgroundMusa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11
“The COVID-19 vaccine was immunogenic in pregnant women, and the vaccine elicited antibodies that were transported to infant cord blood and breast milk.(44) The feasibility of vaccination with DCs loaded with mRNA encoding a defined antigen identified of immunogenic T-cell epitopes.”
BackgroundKatoto, P. D., Brand, A., Byamungu, L. N., Tamuzi, J. L., Mahwire, T. C., Kitenge, M. K., Wiysonge, C. S., & Gray, G. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2144039 · Cited by 12
“Decreased appetite, lethargy, asthenia, malaise, nocturnal sweats, and hyperhidrosis were among the new adverse events due to BNT162b2 that had not been detected in prior investigations.(10)”
InfluentialLee, M., Choi, W., You, S., Park, S., Kim, J.-Y., Nam, D. R., Lee, J. W., & Jung, S. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00742-5 · Cited by 11
“9) corresponds to the results of a randomized controlled trial [5].”
BackgroundMahachi, M., Moukala, H., Ismail, A., Hopf, A., & Ehm, H. (2022) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2022.10.037 · Cited by 11
Herpes Zoster Following COVID-19 Vaccine Booster
Shahrudin, M. S., Mohamed-Yassin, M.-S., & Nasir, N. M. N. M. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.938667 · Cited by 11
“Based on the initial clinical trials, there were no documented cases of herpes zoster from mRNA-based vaccines [17,18].”
Aboud, F. M., Hussein, R. S., & Hassan, R. M. (2022) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2022.12.003 · Cited by 11
“[27] who showed that vaccine was effective in preventing serious illness by 96.”
Naorungroj, T., Viarasilpa, T., Tongyoo, S., Detkaew, A., Pinpak, T., Wimolwattanaphan, R., Ratanarat, R., Promsin, P., Thamrongpiroj, P., Phumpichet, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1061955 · Cited by 7
Zhang, M., Wang, Y., Zhang, T., Zhou, J., Deng, Y., Wang, L., & Du, Y. (2023) · Global Health & Medicine · doi:10.35772/ghm.2022.01063 · Cited by 11
COVID-19 Vaccination and Cardiac Arrhythmias: A Review
Pari, B., Babbili, A., Kattubadi, A., Thakre, A., Thotamgari, S. R., Gopinathannair, R., Olshansky, B., & Dominic, P. S. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01921-7 · Cited by 12
Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients
Al-Shudifat, A.-E., Al‐Tamimi, M., Dawoud, R., Alkhateeb, M., Mryyian, A., Al-Ahmad, A., Abbas, M. M., & Qaqish, A. (2023) · Vaccines · doi:10.3390/vaccines11091398 · Cited by 11
“The subjects who received the third dose of any vaccine were 100% positive for anti-S antibodies, which confirms the importance of the third dose and its ability to boost the immune response and increase the longevity of the antibodies [25].”
Fayad, D., & Frenck, R. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010087 · Cited by 12
Self-citationChimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells
Diwanji, N., Getts, D. R., & Wang, Y. (2024) · ImmunoHorizons · doi:10.4049/immunohorizons.2300099 · Cited by 11
“The success of the mRNA COVID-19 vaccines has fueled the development of RNA-based therapies (7, 8).”
BackgroundStrategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection
Yang, K., Zeng, Y., Wu, X., Li, J., & Guo, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392898 · Cited by 13
Azzolini, E., Canziani, L. M., Voza, A., Desai, A., Pepys, J., Santis, M. D., Ceribelli, A., Pozzi, C., Turato, M., Badalamenti, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10030439 · Cited by 11
“In the case of self-reported items, however, the literature suggests that this approach may lead to an over-response by subjects who experienced adverse events, and this is likely to stress the safety profile of the vaccine [12,13,29].”
BackgroundResultHigh-Speed Railways and the Spread of Covid-19
Pang, J., He, Y., & Shen, S. (2022) · Travel Behaviour and Society · doi:10.1016/j.tbs.2022.08.001 · Cited by 11
Yin, J., Chen, Y., Li, Y., Zhang, X., & Wang, C. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2119763 · Cited by 11
Li, J., Huang, F., Ma, Q., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131051 · Cited by 12
Respecting Conversational Norms Improves Reception of Expert Messages Among Unvaccinated Individuals
McCrea, S. M., Thürmer, J. L., Helm, M. R., Erion, C. J., & Krueger, K. P. (2023) · Health Communication · doi:10.1080/10410236.2023.2243047 · Cited by 11
“Data from clinical trials and the first 5–6 months of administration revealed high efficacy and very low rates of adverse events (El Sahly et al., 2021; Self et al., 2021; Thomas et al., 2021).”
Barlow, R. S., Jian, K., & Larson, L. (2021) · medRxiv · doi:10.1101/2021.08.30.21262446 · Cited by 11
Watanabe, S., & Hama, R. (2022) · medRxiv · doi:10.1101/2022.10.13.22281036 · Cited by 11
Influenza vaccines: where we are, where we are going
Khalil, N., & Bernstein, D. I. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001103 · Cited by 14
Addressing message fatigue for encouraging COVID-19 vaccination
Okuhara, T., Okada, H., & Kiuchi, T. (2023) · Journal of Communications In Healthcare · doi:10.1080/17538068.2023.2207246 · Cited by 10
“Since the e ff ectiveness of COVID-19 vaccines in preventing infection and the onset of disease declines over several months, regular multiple doses of vaccines are recommended [1,2].”
BackgroundNg, M., Tam, C. H., Lee, Y. P., Fong, H. T. A., Wong, C., Ng, W. K. C., Yeung, M. H. Y., Ling, W.-H. I., Tsao, S. S. L., Wan, E. Y. F., et al. (2023) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-023-00985-2 · Cited by 10
“COVID-19 vaccination has a wealth of data showing that it is effective and safe [22, 26, 27].”
BackgroundAliabadi, L. S., Azari, M., Taherian, M. R., Barkhordar, M., Abbas, S. A. M., Azari, M., Ahmadvand, M., Salehi, Z., Rouzbahani, S., & Vaezi, M. (2024) · Virology Journal · doi:10.1186/s12985-024-02375-1 · Cited by 10
“This is due to the recognized phenomenon of vaccine efficacy diminishing over time [18, 19].”
BackgroundBroseta, J. J., Rodríguez‐Espinosa, D., Bedini, J. L., Rodríguez, N., & Maduell, F. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab272 · Cited by 10
Pascucci, D., Nurchis, M. C., Sapienza, M., Castrini, F., Beccia, F., D’Ambrosio, F., Grossi, A., Castagna, C., Pezzullo, A. M., Zega, M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111098 · Cited by 10
Nabeshima, A., Sakamoto, A., Iwata, K., Kitamura, Y., Masui, S., Inomata, S., Iida, M., Iida, T., & Nabeshima, S. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.03.014 · Cited by 10
“Long term, pre-exposure prophylaxis (PrEP) for COVID-19 through vaccination has been shown to be effective [5], however, it is possible that vaccines for COVID-19 will become less effective against SARS-CoV-2 variants that can escape natural or host immunity provided by these vaccines [6–8].”
Long‐term effects of SARS‐CoV ‐2 vaccination in the nursing home setting
Rivasi, G., Bulgaresi, M., Bandinelli, C., Balzi, D., Tarantini, F., Tognelli, S., Lorini, C., Buscemi, P., Baggiani, L., Landini, G., et al. (2022) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17773 · Cited by 10
“A recent update to the preliminary efficacy report of the BNT162b2 described a gradual decline of vaccine efficacy in disease prevention over the 6 months following vaccination, with an average 6% reduction of efficacy, every 2 months.(2) Moreover, available data indicate that the immune response to the BNT162b2 vacci…”
BackgroundMethodInfluentialKuzmina, A., Wattad, S., Engel, S., Rosenberg, E., & Taube, R. (2022) · Viruses · doi:10.3390/v14040803 · Cited by 11
Fiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-10896-4 · Cited by 11
Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
Bansal, D., Abdulmajeed, J., Yassin, E., Al-Shamali, M. H. M. A., Albayat, S. S., Himatt, S. M., Cyprian, F. S., Chivese, T., Mundodan, J. M., Khogali, H., et al. (2022) · Vaccines · doi:10.3390/vaccines10071036 · Cited by 10
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.